Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
Vector Institute, Toronto, ON, Canada.
Blood Cancer J. 2024 Aug 7;14(1):128. doi: 10.1038/s41408-024-01111-w.
Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies.
滤泡性淋巴瘤(FL)在患者间的生物学特征和临床轨迹上存在相当大的可变性。为了剖析 FL 的多样性,我们利用伯努利混合模型在 713 个预处理肿瘤组织样本中识别了遗传亚型。我们的分析揭示了存在五种具有独特遗传特征的亚型,这些特征与临床病理特征相关。这些簇富含特定的突变,如下所示:CS(CREBBP 和 STAT6)、TT(TNFAIP3 和 TP53)、GM(GNA13 和 MEF2B)、Q(静止,突变负担低)和 AR(mTOR 通路相关基因的突变)。亚型 Q 在 I 期疾病患者中富集,与其他亚型相比,其增殖史较低。AR 亚型在 IgM 表达的 FL 病例中富集,与晚期和超过 4 个淋巴结部位相关。在 GALLIUM 试验的 418 个独立样本队列中验证了亚型的存在。值得注意的是,接受免疫化疗治疗的 TT 亚型患者的无进展生存期始终较差。我们的研究结果为每个 FL 簇明显相关的核心途径提供了深入的了解,预计在靶向治疗时代将具有信息性。